Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
07/2003
07/17/2003WO2003057671A1 Biaryl compound and use thereof
07/17/2003WO2003057670A2 Indoles as naaladase inhibitors
07/17/2003WO2003057669A1 Androgen receptor antagonists
07/17/2003WO2003057668A1 Nitrogenous cyclic ketone derivative, process for producing the same, and use
07/17/2003WO2003057666A2 Inhibitors of dipeptidyl peptidase iv
07/17/2003WO2003057255A1 Drugs against obeisty and drugs against fatty liver
07/17/2003WO2003057254A1 Preventives/remedies for urinary disturbance
07/17/2003WO2003057252A1 Human mast cell-expressed membrane proteins
07/17/2003WO2003057250A1 Cancer treatment
07/17/2003WO2003057249A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound
07/17/2003WO2003057228A1 Carbon dioxide compositions for external use and process for producing the same
07/17/2003WO2003057224A1 Apoptosis inductor
07/17/2003WO2003057222A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
07/17/2003WO2003057220A1 Cyclic urea derivatives with 5-ht2c receptor activity
07/17/2003WO2003057219A1 Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder
07/17/2003WO2003057218A1 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
07/17/2003WO2003057217A1 Combinations comprising epothilones and anti-metabolites
07/17/2003WO2003057215A1 Neurotrophic factor production/secretion accelerator
07/17/2003WO2003057211A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases.
07/17/2003WO2003057202A1 Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
07/17/2003WO2003057201A2 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
07/17/2003WO2003057200A2 Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
07/17/2003WO2003057196A1 Drug mixture with enhanced dissolution rate
07/17/2003WO2003057195A1 Pravastatin pharmaceutical formulations and methods of their use
07/17/2003WO2003057170A2 Oral insulin therapy
07/17/2003WO2003057169A2 4-dedimethylamino tetracycline compounds
07/17/2003WO2003057168A2 Cancer-associated epitope
07/17/2003WO2003057166A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
07/17/2003WO2003057163A2 Methods for preparing immunoconjugates
07/17/2003WO2003057153A2 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
07/17/2003WO2003057148A2 Use of biomolecular targets in the treatment and visualization of tumors
07/17/2003WO2003057147A2 Useful aroyl pyrrole heteroaryl methanones and methanols
07/17/2003WO2003057144A2 Change inhibitors of dipeptidyl peptidase iv
07/17/2003WO2003057133A2 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders
07/17/2003WO2003057130A2 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
07/17/2003WO2003057007A2 System for monitoring bacterial tumor treatment
07/17/2003WO2003057006A2 Use of antibodies against the muc18 antigen
07/17/2003WO2003056913A1 Nonhuman model animal lacking the ability to control lymphocyte migration
07/17/2003WO2003056899A2 Nitric oxide donors for treatment of disease and injury
07/17/2003WO2003043974A3 New pharmaceutical compounds
07/17/2003WO2003030827A3 Compositions for and methods of treating and preventing sirs/sepsis
07/17/2003WO2003022809A3 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
07/17/2003WO2003020371A3 Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer
07/17/2003WO2002102340A3 Use of carnitine and/or one or more acyl-carnitines for producing cosmetic or dermatological preparations
07/17/2003WO2002099044A3 B3galts as modifiers of the p53 pathway and methods of use
07/17/2003WO2002090566A3 Recombinant tumor specific antibody and use thereof
07/17/2003WO2002085861A8 Imidazolidine compounds and their use as cxcr3 antagonists
07/17/2003WO2002076434A3 Nicotinic receptor agonists for the treatment of inflammatory diseases
07/17/2003WO2002058323A3 Method for identifying modulators of bace
07/17/2003WO2002055693A3 Method for inhibiting the expression of a target gene
07/17/2003WO2002055496A8 Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
07/17/2003WO2002055495A8 Aryl piperidine derivatives as inducers of ldl-receptor expression
07/17/2003WO2002046190A3 Sulfonamido ether substituted imidazoquinolines
07/17/2003WO2002031134A3 Novel serine protease genes related to dppiv
07/17/2003WO2002029060A9 Hematopoietin receptors hpr1 and hpr2
07/17/2003WO2002026998A3 Hydrolases
07/17/2003WO2002022805A3 Modulation of il-2- and il-15-mediated t cell responses
07/17/2003WO2002017858A9 Role of fosb in bone formation
07/17/2003WO2002011713A3 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists
07/17/2003US20030135063 Especially Type II diabetes; stimulating the kinase activity of the insulin receptor; activating the insulin receptor
07/17/2003US20030135055 Inhibitors of factors Xa and VIIa
07/17/2003US20030135044 Novel gamma secretase inhibitors
07/17/2003US20030134902 Novel dicarboxylic acid derivatives
07/17/2003US20030134899 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect
07/17/2003US20030134898 N-Acetylsulfamic acid derivatives
07/17/2003US20030134891 N,N'-bis(2-carboxytetramethylene)adipamide or cyclic alkylene esters for use in the treatment or prevention of central and systemic amyloidosis.
07/17/2003US20030134889 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
07/17/2003US20030134888 Substituted diaminopyrazoles; treating diseases, such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. coatings for implantable medical devices, such as prostheses, artificial valves, etc.
07/17/2003US20030134887 Orally administering celecoxib formulated in such a way as to provide a blood plasma concentration profile of celecoxib of 250 ng/ml in not later than 30 minutes
07/17/2003US20030134886 Pharmaceutically active compounds
07/17/2003US20030134880 Novel cd23 inhibitors
07/17/2003US20030134879 Substituted with a thio, sulfoxy or sulfonyl group
07/17/2003US20030134878 Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith
07/17/2003US20030134876 Inhibiting TNF alpha
07/17/2003US20030134873 8-phenyl-(1,2,4)triazolo(1,5-a)pyridin-2-yl)-benzamide derivatives
07/17/2003US20030134868 Prevention of addiction in pain management
07/17/2003US20030134865 Modulation of histone deacetylase
07/17/2003US20030134861 Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction
07/17/2003US20030134859 Substituted 2-chloro-5-nitrobenzamides; treating retrograde osteoporosis and diabetes mellitus
07/17/2003US20030134856 Method and structure for inhibiting activity of serine elastases
07/17/2003US20030134855 P-acylaminomethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2 -yl)-benzamides; treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, Parkinson's and ADHD
07/17/2003US20030134854 Treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, neuroprotection, Parkinson's disease, and attention deficit hyperactivity disorder.
07/17/2003US20030134850 Hydrazinyl and nitrogen oxide pyrazoles
07/17/2003US20030134849 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
07/17/2003US20030134847 New polycyclic azaindole compounds
07/17/2003US20030134840 Novel compounds
07/17/2003US20030134839 5-(Alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles
07/17/2003US20030134837 Pharmaceutically acceptable salts thereof; their use as inhibitors of Raf kinases and pharmaceutical compositions containing them and anticancer agents
07/17/2003US20030134836 Substituted arylamine derivatives and methods of use
07/17/2003US20030134821 Promoters of neural regeneration
07/17/2003US20030134820 Promoting neural cell growth and/or regeneration. The general methods involve contacting with an activator of a cyclic nucleotide dependent protein kinase a neural cell subject to growth repulsion mediated by a neural cell growth repulsion
07/17/2003US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as
07/17/2003US20030134802 Novel effectors of dipepetidyl peptidase IV
07/17/2003US20030134801 Pharmaceutical compositions containing them are of the class of thrombin inhibitors which are useful as anticoagulants.
07/17/2003US20030134800 Physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. composition weight, (2) hydroxynaphthoic acid
07/17/2003US20030134799 Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
07/17/2003US20030134796 Antithrombin for the prevention and therapy of vasculoproliferative disorders
07/17/2003US20030134792 Compositions and methods for treating articular cartilage disorders
07/17/2003US20030134789 Compositions and methods for protecting tissues and cells from damage, and for repairing damaged tissues
07/17/2003US20030134779 Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections
1 ... 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 ... 1564